BenevolentAI: Result of Annual General Meeting
May 02 2024 - 9:30AM
Business Wire
Regulatory News:
BenevolentAI (“BenevolentAI” or the “Company”) (Euronext
Amsterdam: BAI), a leader in applying advanced AI to accelerate
biopharma drug discovery announces that all resolutions proposed at
its Annual General Meeting held today were duly passed. The voting
results will be made available shortly on the Company’s website
(www.benevolent.com/investors/general-meetings/), where the full
documentation regarding the AGM can also be found.
In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth
Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the
Board of the Company as Non-Executive Directors. As per the
Company’s announcement of 15 April 2024, the close of the AGM has
also resulted in the resignations of Dr François Nader, Dr Olivier
Brandicourt, Dr Susan Liautaud and Mr Marcello Damiani, as
Non-Executive Directors of BenevolentAI, becoming effective. The
Board now consists of eight persons, seven Non-Executive Directors
and Dr Joerg Moeller, CEO and Executive Director of the Company.
The position of the Chair of the Board and the composition of Board
Committees will be determined at the time of the first board
meeting and will be communicated thereafter.
Dr Joerg Moeller, Chief Executive Officer of BenevolentAI,
said:
“Whilst I have only been at the Company since the beginning of
the year, on behalf of everyone at BenevolentAI, I want to thank
Francois, Olivier, Susan and Marcello for their dedication,
stewardship and insights over the last several years. In
particular, I want to recognize François’ important contribution as
Acting CEO in the period immediately prior to my appointment and in
onboarding me as CEO of BenevolentAI.
“I also want to take this opportunity to welcome Peter, Ken, Ian
and Jeremy to the Board. I look forward to working closely with
them as we continue to focus on executing BenevolentAI’s strategy
and on our mission of uniting science and technology to build a
leader in AI augmented drug discovery to deliver life-changing
medicines to patients.”
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our
proprietary and validated Benevolent PlatformTM that integrates AI
and science to uncover new biology, predict novel targets and
develop first-in-class or best-in-class drugs for complex diseases.
By applying proprietary advanced AI tools, in combination with
in-house scientific expertise and wet-lab facilities, BenevolentAI
is well-positioned to identify and accelerate novel drug discovery.
The Company’s business model presents multiple routes for value
creation, including discovery collaborations with pharma companies
like AstraZeneca and Merck and advancing in-house pipelines to
inflection points. Headquartered in London, with wet labs in
Cambridge (UK), BenevolentAI is at the forefront of reshaping the
future of drug discovery and delivering innovative medicines.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502696991/en/
Enquiries: Investors: Catherine Isted – Chief
Financial Officer investors@benevolent.ai T: +44(0) 203 781
9360
Company Secretary: Judit Molnar – Deputy Company
Secretary cosec@benevolent.ai T: +44(0) 203 781 9360
Media: Rachel Gurney press@benevolent.ai T: +44(0) 203
781 9360
FTI Consulting: Ben Atwell/Simon Conway/Victoria Foster
Mitchell T: +44 203 727 1000 BenevolentAI@fticonsulting.com